Bayer Grants4Apps® Dealmaker Berlin 2017

Bayer Grants4Apps® is calling all mature teams, startups and companies that have a solution ready to go. The new Dealmaker is all about quality facetime between you and Grants4Apps' experts for one full day. If there is a match, you will be invited to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey.

Grants4Apps team has put together specific challenges, applicants are asked to address one or multiple of these challenges below. However, the team is also open for other solutions that help healthcare providers or patients, as well as products dedicated to preventing or diagnosing diseases or improving pharmaceutical processes.

The Challenges

Hemophilia

  • Empower hemophilia (bleeding disease) patients to individually adjust their treatment regimen to lead active lives.

Women's Health

  • Enabling earlier diagnosis of endometriosis.
  • Enhancing intrauterine device insertion training for providers.
  • Providing effective contraceptive counseling (face to face, remote or automated).
  • Improving comfort and experience during intrauterine device insertion for both providers & patients.
  • Simplifying the thread/placement check post-insertion of intrauterine devices.

Pulmonology

  • Improve identification of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) patients.
  • Improve adherence for an oral pulmonary hypertension treatment.
  • Innovative and efficient concepts for training staff to use a drug and device combination product in an intensive care unit setting.
  • Create awareness for limited outcome of standard of care treatment for pneumonia in the hospital.

Ophthalmology

  • Remote/mobile screening for Diabetic Retinopathy.
  • Remote monitoring of patients treated with anti-Vascular Endothelial Growth Factors (VEGFs).
  • Utilizing real-world evidence (RWE) to predict the need for anti-Vascular Endothelial Growth Factors (VEGFs)-injections.

Nephrology

  • Monitoring of chronic kidney disease (CKD).
  • Diagnosis of acute kidney injury.

Artificial Intelligence

  • Prediction of combination therapies for cancer.
  • Extract compound structures and Structure-Activity Relationship (SAR) data from patents.
  • Computer-assisted identification of new compounds for protein targets.
  • Develop analysis tool for in vivo experiments.

Data Analytics

  • Data analysis tools to systematically identify worldwide activities in Research & Development.
  • Deep Learning Research Services for health and life science data.
  • Transforming Electronic Health Records (EHR) data to analysis data sets.
  • Analyze drug labels to generate new insights.
  • Develop efficient analysis of large scientific literature corpi to generate insights.
  • How to implement prediction algorithms in hospital information systems.
  • Social Media use in pharma.

Clinical Trials

  • Patient identification and recruitment for clinical trials.
  • Improving the patient experience in clinical trials.
  • Develop a mobile platform for patients to report their health condition parameters.
  • Adherence improvement in (clinical trials OR) real life.

Submission deadline: 30 June 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/dealmaker-berlin-2017/

About Grants4Apps®
We connect health startups with industry experts and help the best talents to thrive within the digital healthcare universe. We are looking for startups beyond the ideation phase developing health technology or IT solutions that can connect and empower patients or healthcare stakeholders.

There are no boundaries to creativity!

Most Popular Now

FDA approves Vosevi for Hepatitis C

The U.S. Food and Drug Administration has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mil...

Green tea ingredient may ameliorate memory impairm…

A study published online in The FASEB Journal, involving mice, suggests that EGCG (epigallocatechin-3-gallate), the most abundant catechin and biologically active compone...

New way found to boost immunity in fight cancer an…

An international research team led by Université de Montréal medical professor Christopher Rudd, director of research in immunology and cell therapy at Maisonneuve-Rosemo...

Amgen and Array BioPharma announce preclinical lic…

Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders...

Merck and Pfizer collaborate with Corning

Merck (NYSE: MRK), Pfizer (NYSE: PFE) and Corning Incorporated (NYSE: GLW) today announced collaborations that have enabled the modernization of pharmaceutical packaging ...

Americans say discussions about clinical trials sh…

An overwhelming majority of Americans (86%) agree that health care professionals should discuss clinical trials with patients diagnosed with a disease as part of their st...

One minute of running per day associated with bett…

A single minute of exercise each day is linked to better bone health in women, new research shows. Scientists from the University of Exeter and the University of Leiceste...

AstraZeneca and Merck establish strategic oncology…

AstraZeneca and Merck & Co., Inc., (Merck; known as MSD outside of the US and Canada) today announced that they have entered a global strategic oncology collaboration to ...

27 Phase III and 8 Phase II Alzheimer's drugs on t…

Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheime...

New drug may treat and limit progression of Parkin…

Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially ...

Johnson & Johnson announces encouraging first-…

Johnson & Johnson has announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Compani...

How physical exercise prevents dementia

Numerous studies have shown that physical exercise seems beneficial in the prevention of cognitive impairment and dementia in old age. Now researchers at Goethe Universit...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]